{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:07:50Z","timestamp":1789092470828,"version":"build-2803163510"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijbiomac.2026.153537","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T23:34:38Z","timestamp":1783985678000},"page":"153537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Therapeutic platforms for cancer management centered on blocking the PD-L1\/PD-1 interaction through the use of aptamers: A review"],"prefix":"10.1016","volume":"376","author":[{"given":"Abolfazl","family":"Marvizadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Sameiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Teymour","family":"Najjarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Alibolandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ramezani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil","family":"Abnous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Mohammad","family":"Taghdisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2026.153537_bb0005","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.etap.2018.08.018","article-title":"Hazardous effects of chemical pesticides on human health\u2013Cancer and other associated disorders","volume":"63","author":"Sabarwal","year":"2018","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2019.06.033","article-title":"Emerging trends in the novel drug delivery approaches for the treatment of lung cancer","volume":"309","author":"Sharma","year":"2019","journal-title":"Chem. Biol. Interact."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153537_bb0015","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1177\/1534735418786801","article-title":"Clinical benefits of acupuncture for the reduction of hormone therapy\u2013related side effects in breast cancer patients: a systematic review","volume":"17","author":"Pan","year":"2018","journal-title":"Integr. Cancer Ther."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153537_bb0020","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s12672-025-02198-8","article-title":"Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy","volume":"16","author":"Zafar","year":"2025","journal-title":"Discov. Oncol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153537_bb0025","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ijpharm.2013.02.020","article-title":"Towards more effective advanced drug delivery systems","volume":"454","author":"Crommelin","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0030","doi-asserted-by":"crossref","first-page":"7291","DOI":"10.2147\/IJN.S146315","article-title":"Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors","author":"Din","year":"2017","journal-title":"Int. J. Nanomedicine"},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.153537_bb0035","doi-asserted-by":"crossref","first-page":"582","DOI":"10.3748\/wjg.v22.i2.582","article-title":"Insight to drug delivery aspects for colorectal cancer","volume":"22","author":"Gulbake","year":"2016","journal-title":"World J. Gastroenterol."},{"issue":"13","key":"10.1016\/j.ijbiomac.2026.153537_bb0040","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2174\/0929867325666181008142831","article-title":"Aptamer-based targeted drug delivery systems: current potential and challenges","volume":"27","author":"He","year":"2020","journal-title":"Curr. Med. Chem."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.153537_bb0045","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.327","article-title":"Nanoparticles-induced potential toxicity on human health: applications, toxicity mechanisms, and evaluation models","volume":"4","author":"Xuan","year":"2023","journal-title":"MedComm"},{"issue":"2021","key":"10.1016\/j.ijbiomac.2026.153537_bb0050","article-title":"Toxicity of nanoparticles in biomedical application: nanotoxicology","volume":"1","author":"Egbuna","year":"2021","journal-title":"J. Toxicol."},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0055","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.addr.2017.01.001","article-title":"Molecular links among non-biodegradable nanoparticles, reactive oxygen species, and autophagy","volume":"122","author":"Anozie","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0060","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.addr.2018.09.011","article-title":"Aptamer-guided nanomedicines for anticancer drug delivery","volume":"134","author":"Alshaer","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.153537_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24050941","article-title":"Recent advances in aptamer discovery and applications","volume":"24","author":"Zhang","year":"2019","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153537_bb0070","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrd.2016.199","article-title":"Aptamers as targeted therapeutics: current potential and challenges","volume":"16","author":"Zhou","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.153537_bb0075","doi-asserted-by":"crossref","first-page":"423","DOI":"10.4062\/biomolther.2013.085","article-title":"Nucleic acid aptamers: new methods for selection, stabilization, and application in biomedical science","volume":"21","author":"Kong","year":"2013","journal-title":"Biomol. Ther."},{"issue":"4 (19)","key":"10.1016\/j.ijbiomac.2026.153537_bb0080","doi-asserted-by":"crossref","first-page":"34","DOI":"10.32607\/20758251-2013-5-4-34-43","article-title":"Aptamers: problems, solutions and prospects","volume":"5","author":"Lakhin","year":"2013","journal-title":"Acta Nat."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153537_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10030080","article-title":"Aptamer therapeutics in cancer: current and future","volume":"10","author":"Morita","year":"2018","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153537_bb0090","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","article-title":"Tumour-intrinsic resistance to immune checkpoint blockade","volume":"20","author":"Kalbasi","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.153537_bb0095","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/08820139.2020.1744639","article-title":"Development and evaluation of novel aptamers specific for human PD1 using hybrid systematic evolution of ligands by exponential enrichment approach","volume":"49","author":"Khedri","year":"2020","journal-title":"Immunol. Investig."},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.153537_bb0100","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1007\/s00604-017-2436-4","article-title":"An aptamer for recognizing the transmembrane protein PDL-1 (programmed death-ligand 1), and its application to fluorometric single cell detection of human ovarian carcinoma cells","volume":"184","author":"Yazdian-Robati","year":"2017","journal-title":"Microchim. Acta"},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153537_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/ph11030086","article-title":"Aptamers as diagnostic tools in cancer","volume":"11","author":"Ruiz Ciancio","year":"2018","journal-title":"Pharmaceuticals"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.153537_bb0110","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153537_bb0120","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0125","article-title":"The role of PD-1 signaling in health and immune-related diseases","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.153537_bb0130","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000464353","article-title":"PD-1\/PD-L1 pathway in breast cancer","volume":"40","author":"Sch\u00fctz","year":"2017","journal-title":"Oncol. Res. Treat."},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.153537_bb0135","doi-asserted-by":"crossref","first-page":"16824","DOI":"10.1002\/jcp.28358","article-title":"PD-1\/PD-L1 pathway: basic biology and role in cancer immunotherapy","volume":"234","author":"Salmaninejad","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.153537_bb0140","first-page":"1764","article-title":"PD-L1 expression in colon cancer and its relationship with clinical prognosis","volume":"12","author":"Shan","year":"2019","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"12","key":"10.1016\/j.ijbiomac.2026.153537_bb0145","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09.010","article-title":"Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer","volume":"39","author":"Zhang","year":"2021","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.153537_bb0150","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1007\/s00432-022-04298-2","article-title":"Characterization of PDL1 enhanced siRNA\/albumin liposome for effective therapeutic function in lung cancer","volume":"149","author":"Zhang","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122283","article-title":"Inhalable pH-responsive DNA tetrahedron nanoplatform for boosting anti-tumor immune responses against metastatic lung cancer","volume":"301","author":"Fan","year":"2023","journal-title":"Biomaterials"},{"issue":"32","key":"10.1016\/j.ijbiomac.2026.153537_bb0160","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202401563","article-title":"A responsive DNA hydrogel containing poly-aptamers as dual-target inhibitors for localized cancer immunotherapy","volume":"34","author":"Zhang","year":"2024","journal-title":"Adv. Funct. Mater."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153537_bb0165","doi-asserted-by":"crossref","DOI":"10.1186\/s12645-023-00239-x","article-title":"Novel nanotherapeutics for cancer immunotherapy by albumin nanoparticles functionalized with PD-1 and PD-L1 aptamers","volume":"15","author":"Jiang","year":"2024","journal-title":"Cancer Nanotechnol."},{"issue":"14","key":"10.1016\/j.ijbiomac.2026.153537_bb0170","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1039\/D3AY02196C","article-title":"Sandwich-type aptamer-based biosensors for thrombin detection","volume":"16","author":"Samani","year":"2024","journal-title":"Anal. Methods"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153537_bb0175","first-page":"107","article-title":"Aptamers and antibodies: rivals or allies in cancer targeted therapy?","volume":"2","author":"Agnello","year":"2021","journal-title":"Explor. Target. Anti-tumor Ther."},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0180","series-title":"The Structure of a Typical Antibody Molecule, Immunobiology: The Immune System in Health and Disease","author":"Janeway","year":"2001"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.153537_bb0185","article-title":"Antibody structure and function: the basis for engineering therapeutics","volume":"8","author":"Chiu","year":"2019","journal-title":"Antibodies (Basel, Switzerland)"},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0190","doi-asserted-by":"crossref","first-page":"13437","DOI":"10.2147\/IJN.S547463","article-title":"Innovative applications of nucleic acid aptamers in colorectal Cancer diagnosis and therapy: from selection optimization to clinical translation","author":"Lu","year":"2025","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0195","series-title":"A therapeutic battle: antibodies vs. Aptamers, Nanosci. Master Progr 109","first-page":"1","author":"Hidding","year":"2017"},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0200","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.omto.2019.06.002","article-title":"A PD-L1-based cancer vaccine elicits antitumor immunity in a mouse melanoma model","volume":"14","author":"Lin","year":"2019","journal-title":"Mol. Ther. Oncol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.153537_bb0205","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000255","article-title":"Targeting immune checkpoints in breast cancer: an update of early results","volume":"2","author":"Solinas","year":"2017","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.153537_bb0210","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1513\/AnnalsATS.201702-152FR","article-title":"The era of checkpoint blockade in lung cancer: taking the brakes off the immune system","volume":"14","author":"Moon","year":"2017","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153537_bb0215","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1021\/acs.molpharmaceut.5b00677","article-title":"Glycyrrhetinic acid mediated drug delivery carriers for hepatocellular carcinoma therapy","volume":"13","author":"Cai","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114238","article-title":"Why nanoparticles prefer liver macrophage cell uptake in vivo","volume":"185","author":"Ngo","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.153537_bb0225","doi-asserted-by":"crossref","DOI":"10.3390\/mi14020451","article-title":"Gold nanoparticles as drug carriers: the role of silica and PEG as surface coatings in optimizing drug loading","volume":"14","author":"Carre\u00f3n Gonz\u00e1lez","year":"2023","journal-title":"Micromachines"},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.153537_bb0230","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1039\/D0BM02221G","article-title":"Strategies for the design of nanoparticles: starting with long-circulating nanoparticles, from lab to clinic","volume":"9","author":"Wang","year":"2021","journal-title":"Biomater. Sci."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.153537_bb0235","doi-asserted-by":"crossref","DOI":"10.1088\/2057-1976\/ac682c","article-title":"Drug-delivery nanoparticles for bone-tissue and dental applications","volume":"8","author":"Higino","year":"2022","journal-title":"Biomed. Phys. Eng. Express"},{"issue":"39","key":"10.1016\/j.ijbiomac.2026.153537_bb0240","doi-asserted-by":"crossref","first-page":"44183","DOI":"10.1021\/acsami.2c12774","article-title":"Photocontrolled spatiotemporal delivery of DNA immunomodulators for enhancing membrane-targeted tumor photodynamic immunotherapy","volume":"14","author":"Wang","year":"2022","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"22","key":"10.1016\/j.ijbiomac.2026.153537_bb0245","doi-asserted-by":"crossref","first-page":"8391","DOI":"10.1021\/jacs.1c02016","article-title":"Aptamer-based logic computing reaction on living cells to enable non-antibody immune checkpoint blockade therapy","volume":"143","author":"Yang","year":"2021","journal-title":"J. Am. Chem. Soc."},{"issue":"29","key":"10.1016\/j.ijbiomac.2026.153537_bb0250","doi-asserted-by":"crossref","first-page":"12120","DOI":"10.1002\/ange.202002145","article-title":"Equipping natural killer cells with specific targeting and checkpoint blocking aptamers for enhanced adoptive immunotherapy in solid tumors","volume":"132","author":"Zhang","year":"2020","journal-title":"Angew. Chem."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.153537_bb0255","doi-asserted-by":"crossref","first-page":"5808","DOI":"10.1021\/acsnano.2c12313","article-title":"Bioorthogonal activation of TLR7 agonists provokes innate immunity to reinforce aptamer-based checkpoint blockade","volume":"17","author":"Wei","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0260","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jconrel.2022.06.039","article-title":"Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression","volume":"348","author":"Kim","year":"2022","journal-title":"J. Control. Release"},{"issue":"45","key":"10.1016\/j.ijbiomac.2026.153537_bb0265","first-page":"24506","article-title":"Covalent LYTAC enabled by DNA aptamers for immune checkpoint degradation therapy","volume":"145","author":"Li","year":"2023","journal-title":"J. Am. Chem. Soc."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.153537_bb0270","article-title":"PD-L1 aptamer-functionalized metal\u2013organic framework nanoparticles for robust photo-immunotherapy against cancer with enhanced safety","volume":"62","author":"Zhang","year":"2023","journal-title":"Angew. Chem. Int. Ed."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153537_bb0275","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1038\/s41467-023-42883-2","article-title":"Inhibition of glycolysis-driven immunosuppression with a nano-assembly enhances response to immune checkpoint blockade therapy in triple negative breast cancer","volume":"14","author":"Ren","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123168","article-title":"A novel FTO-targeting nanodrug induces disulfidptosis and ameliorates the suppressive tumor immune environment to treat uveal melanoma","volume":"319","author":"Tian","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0285","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202419969","article-title":"Cell surface-tethered nucleic acid therapeutics program robust and tumor-responsive enhancement of adoptive cell therapy","volume":"37","author":"Gao","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115569","article-title":"The therapeutic potential of PD-1\/PD-L1 pathway on immune-related diseases: based on the innate and adaptive immune components","volume":"167","author":"Zhang","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0295","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1414900","article-title":"PD-1 expression in tumor infiltrating lymphocytes as a prognostic marker in early-stage non-small cell lung cancer","volume":"14","author":"Dan","year":"2024","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153537_bb0300","doi-asserted-by":"crossref","first-page":"73","DOI":"10.21147\/j.issn.1000-9604.2025.01.06","article-title":"Composite score of PD-1+ CD8+ tumor-infiltrating lymphocytes and CD57+ CD8+ tumor ascites lymphocytes is associated with prognosis and tumor immune microenvironment of patients with advanced high-grade serous ovarian cancer","volume":"37","author":"He","year":"2025","journal-title":"Chin. J. Cancer Res."},{"issue":"21","key":"10.1016\/j.ijbiomac.2026.153537_bb0305","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17213485","article-title":"Assessment of the PD-1\/PD-L1\/PD-L2 immune checkpoints pathway in endometrial cancer and its clinical significance","volume":"17","author":"W\u0142odarczyk-Cieka\u0144ska","year":"2025","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.153537_bb0310","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.31557\/APJCP.2024.25.10.3471","article-title":"The expression of PDL-1 and PD1 in the microenvironment of oral squamous cell carcinoma","volume":"25","author":"Wahbi","year":"2024","journal-title":"Asian Pac. J. Cancer Prevent."},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.153537_bb0315","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1073\/pnas.0712278105","article-title":"The PD-1\/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors","volume":"105","author":"Lin","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.153537_bb0320","first-page":"347","article-title":"Recombinant expression and purification of extracellular domain of the programmed cell death protein receptor","volume":"8","author":"Zhansaya","year":"2020","journal-title":"Rep. Biochem. Mol. Biol."},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119359","article-title":"Cas9-edited immune checkpoint blockade PD-1 DNA polyaptamer hydrogel for cancer immunotherapy","volume":"218","author":"Lee","year":"2019","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153537_bb0330","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1124\/pharmrev.121.000349","article-title":"Matrix metalloproteinases: from molecular mechanisms to physiology, pathophysiology, and pharmacology","volume":"74","author":"de Almeida","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0335","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.11","article-title":"Targeting the PD-1\/PD-L1 immune evasion axis with DNA aptamers as a novel therapeutic strategy for the treatment of disseminated cancers","volume":"4","author":"Prodeus","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.153537_bb0340","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1039\/C6NR07315H","article-title":"Nanocaged platforms: modification, drug delivery and nanotoxicity. Opening synthetic cages to release the tiger","volume":"9","author":"Zangabad","year":"2017","journal-title":"Nanoscale"},{"issue":"41","key":"10.1016\/j.ijbiomac.2026.153537_bb0345","article-title":"Robust, reproducible, and scalable synthesis of silver nanocubes","volume":"30","author":"Zhang","year":"2024","journal-title":"Chemistry (Weinheim an der Bergstrasse, Germany)"},{"issue":"13","key":"10.1016\/j.ijbiomac.2026.153537_bb0350","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2217\/nnm-2016-0109","article-title":"Putting gold nanocages to work for optical imaging, controlled release and cancer theranostics","volume":"11","author":"Pang","year":"2016","journal-title":"Nanomedicine"},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.153537_bb0355","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/smll.200902216","article-title":"Gold nanocages as photothermal transducers for cancer treatment","volume":"6","author":"Chen","year":"2010","journal-title":"Small"},{"issue":"38","key":"10.1016\/j.ijbiomac.2026.153537_bb0360","doi-asserted-by":"crossref","first-page":"42931","DOI":"10.1021\/acsami.2c11089","article-title":"Aptamer-gold nanocage composite for photoactivated immunotherapy","volume":"14","author":"Song","year":"2022","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153537_bb0365","doi-asserted-by":"crossref","DOI":"10.1186\/s12645-023-00177-8","article-title":"Novel bispecific aptamer targeting PD-1 and nucleolin for cancer immunotherapy","volume":"14","author":"Fu","year":"2023","journal-title":"Cancer Nanotechnol."},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0370","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.omtn.2022.01.008","article-title":"Cancer immunomodulation using bispecific aptamers","volume":"27","author":"Thomas","year":"2022","journal-title":"Mol. Ther.\u2013Nucleic Acids"},{"issue":"12","key":"10.1016\/j.ijbiomac.2026.153537_bb0375","doi-asserted-by":"crossref","first-page":"21129","DOI":"10.1021\/acsnano.2c09093","article-title":"Bispecific aptamer-based recognition-then-conjugation strategy for PD1\/PDL1 axis blockade and enhanced immunotherapy","volume":"16","author":"Sun","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122924","article-title":"Nanoradiosentizers with X ray-actuatable supramolecular aptamer building units for programmable immunostimulatory T cell engagement","volume":"315","author":"He","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0385","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12943-026-02648-z","article-title":"CAR-NK cell therapy for hematologic malignancies: advances, challenges and optimization strategies","volume":"25","author":"Liu","year":"2026","journal-title":"Mol. Cancer"},{"issue":"29","key":"10.1016\/j.ijbiomac.2026.153537_bb0390","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2426724122","article-title":"In vivo generation of CAR macrophages via the enucleated mesenchymal stem cell delivery system for glioblastoma therapy","volume":"122","author":"Zhou","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"16","key":"10.1016\/j.ijbiomac.2026.153537_bb0395","doi-asserted-by":"crossref","first-page":"10878","DOI":"10.1021\/acs.jmedchem.3c00551","article-title":"Aptamers targeting the PD-1\/PD-L1 axis: a perspective","volume":"66","author":"Bertrand","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0400","article-title":"Aptamers as immune checkpoint inhibitors in cancer immunotherapy: targeting CTLA-4\/B7 and PD-1\/PD-L1 pathways","volume":"164","author":"Rajah","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153537_bb0405","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0281143","article-title":"Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors","volume":"18","author":"Maekawa","year":"2023","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.153537_bb0410","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17080948","article-title":"Aptamers targeting immune checkpoints for tumor immunotherapy","volume":"17","author":"Abdu","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2026.119299","article-title":"Aptamers in cancer therapy: why has clinical translation lagged behind preclinical promise?","volume":"198","author":"Tran","year":"2026","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0420","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.csbj.2019.03.006","article-title":"Application of PD-1 blockade in cancer immunotherapy","volume":"17","author":"Wu","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153537_bb0425","article-title":"Expanding the reach of monoclonal antibodies: a review of synthetic nucleic acid delivery in immunotherapy","volume":"12","author":"Chung","year":"2023","journal-title":"Antibodies (Basel, Switzerland)"},{"issue":"13","key":"10.1016\/j.ijbiomac.2026.153537_bb0430","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25136833","article-title":"New insights into aptamers: an alternative to antibodies in the detection of molecular biomarkers","volume":"25","author":"Domsicova","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0435","article-title":"Aptamers as target-specific recognition elements in drug delivery","volume":"226","author":"Otu","year":"2025","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.ab.2025.115844","article-title":"Recent advancements in aptamers as promising nanotool for therapeutic and diagnostic applications","volume":"702","author":"Alsaidan","year":"2025","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0445","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.mattod.2025.06.020","article-title":"Aptamers in drug delivery development","volume":"88","author":"Wen","year":"2025","journal-title":"Mater. Today"},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2019.111662","article-title":"DNA origami-based aptasensors","volume":"143","author":"Sameiyan","year":"2019","journal-title":"Biosens. Bioelectron."},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0455","article-title":"Applications of aptamers in pharmaceutical analysis: comprehensively empowering drug development","volume":"268","author":"Cheng","year":"2025","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153537_bb0460","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1517\/13543784.17.1.43","article-title":"Therapeutic applications of aptamers","volume":"17","author":"Kaur","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0465","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.2147\/IJN.S507715","article-title":"Recent advances in aptamers-based nanosystems for diagnosis and therapy of cardiovascular diseases: an updated review","author":"Yu","year":"2025","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0470","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1536569","article-title":"Aptamer based immunotherapy: a potential solid tumor therapeutic","volume":"16","author":"Mathavan","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0475","article-title":"Aptamer\u2013liposome targeted nanotherapeutics for cancer therapy: bibliometric analysis, recent developments and future perspectives","volume":"36","author":"Gao","year":"2026","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2025.116787","article-title":"Advances in aptamer-based biosensors for cancer biomarker detection: a systematic review of emerging technologies and translational potential","volume":"221","author":"Lukman","year":"2026","journal-title":"Microchem. J."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153537_bb0485","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3892\/ol.2025.15071","article-title":"Application of multivalent aptamers in tumor diagnosis, analysis and therapy","volume":"30","author":"Zeng","year":"2025","journal-title":"Oncol. Lett."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153537_bb0490","article-title":"Aptamer-guided CRISPR systems delivery: precision targeting strategies, translational barriers, and therapeutic potential","volume":"9","author":"Ijjeh","year":"2026","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2025.115639","article-title":"Aptamer-based applications in delivering cancer gene therapies and beyond: state of the art and the missing links to clinical translation","volume":"224","author":"Coppola","year":"2025","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2026.153537_bb0500","article-title":"Nuclear-targeted CRISPR\/Cas delivery by using aptamer-modified polymer lipid nanoparticles","volume":"74","author":"Xu","year":"2026","journal-title":"Nanomedicine"}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026034823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026034823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T01:53:18Z","timestamp":1789091598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813026034823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":100,"alternative-id":["S0141813026034823"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.153537","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic platforms for cancer management centered on blocking the PD-L1\/PD-1 interaction through the use of aptamers: A review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.153537","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"153537"}}